Results 101 to 110 of about 14,647 (219)

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis [PDF]

, 2007
Wolfgang Wienen, J M Stassen, Henning Priepke, Uwe J. Ries, Norbert Hauel   +4 more
openalex   +1 more source

Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

Medicina, 2019
Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins ...
Gintautas Gumbrevičius, Gytė Damulevičienė, Vaidotas Galaunė, Milda Gumbrevičiūtė   +3 more
doaj   +1 more source

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +1 more source

Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need? [PDF]

, 2009
Russell D. Hull
openalex   +1 more source

The level is in the details: Why differences between direct‐acting oral anticoagulants should be considered in the treatment of patients with epilepsy

Epilepsia, Volume 65, Issue 12, Page 3474-3483, December 2024.
Hagar Cohen, Nahawand Bahash, Bruria Raccah, Ilan Matok, Dana Ekstein, Lee Goldstein, Yosef Kalish, Sara Eyal   +7 more
wiley   +1 more source

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage

Clinical Practice and Cases in Emergency Medicine, 2017
Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Jonathan Balakumar, Ruben Santiago, Mark Supino   +2 more
doaj   +1 more source

Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.

Drug Metabolism and Pharmacokinetics, 2022
S. Laizure, F. Chen, J. Farrar, Dina Ali, Binghua Yang, R. Parker   +5 more
semanticscholar   +1 more source

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal [PDF]

, 2011
Karl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul, Paul Reilly, Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, Lars Wallentin, Sebastian Haertter, Alexander Staab   +9 more
openalex   +1 more source

Use of oral anticoagulants after intramedullary nailing of femur and tibial fractures in trauma department

Travmatologiâ i Ortopediâ Rossii, 2016
The authors evaluated of the effectiveness of new oral anticoagulants in patients with diaphyseal fractures of the femur and tibia.We analyzed the effectiveness of thromboprophylaxis in 85 patients with diaphyseal fractures of the femur and tibia in the ...
A. K. Dulaev, A. N. Tsed, I. G. Dzhusoev
doaj  

Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate [PDF]

, 2012
Melissa D. Lambourne, Louise J. Eltringham‐Smith, Sharon Gataiance, Donald M. Arnold, Mark Crowther, William P. Sheffield   +5 more
openalex   +1 more source